EMAIL THIS PAGE TO A FRIEND

EMBO molecular medicine

Treatment of hypertension by increasing impaired endothelial TRPV4-KCa2.3 interaction.


PMID 28899928

Abstract

The currently available antihypertensive agents have undesirable adverse effects due to systemically altering target activity including receptors, channels, and enzymes. These effects, such as loss of potassium ions induced by diuretics, bronchospasm by beta-blockers, constipation by Ca